Visikol’s Continued Development of Blood Brain Barrier Model
Carol Tomaszewski2022-11-14T10:42:52-05:00Each morning the first thing a person does is think about their day. It may start with making coffee [...]
Visikol’s Commitment to Reducing Animals in Research
Carol Tomaszewski2022-05-26T07:45:17-05:00Like many of the BICO companies, Visikol is highly focused on reducing the usage of animals in research and [...]
Visikol to Present at the 5th Annual Drug Discovery & Development Conference
Carol Tomaszewski2022-02-14T09:27:41-05:00Labroots Drug Discovery & Development 2022 Labroots and the Drug Discovery planning committee are pleased [...]
2D vs 3D In Vitro Models for Use in Drug Discovery
Carol Tomaszewski2022-01-31T09:54:07-05:00Figure 1: Differential proliferative response in 2D vs. 3D cell culture The drug discovery and development process is [...]
Visikol to present at SELECTBIO’s December 2021 Conference
Carol Tomaszewski2021-11-05T15:34:56-05:00Visikol's Director of Drug Discovery, Peter Worthington Ph.D., to Present at SELECTBIO's 3D-Cell Culture, Organoids, and Organs-on-Chips Conference [...]
Increasingly Positive Cancer Outcomes Puts Cardiac Side Effects Center Stage
Mike Johnson2020-07-15T15:01:34-05:00The five-year relative survival for all cancer sites has been steadily improving since the 1980s. Because cancer is becoming [...]
Cell Viability Assays for 3D Cell Culture
Mike Johnson2019-10-14T11:39:35-05:00One of the most common assays used with in vitro models is an assessment of total ATP which is [...]
Optics based endpoints: a balance between resolution and throughput
Mike Johnson2019-07-24T13:14:02-05:00As drug discovery and development efforts continue to seek balance between throughput and translatability of in vitro studies to [...]